CN1371682A - Compound zinc undecylenate ointment for treating beriberi - Google Patents
Compound zinc undecylenate ointment for treating beriberi Download PDFInfo
- Publication number
- CN1371682A CN1371682A CN 01106754 CN01106754A CN1371682A CN 1371682 A CN1371682 A CN 1371682A CN 01106754 CN01106754 CN 01106754 CN 01106754 A CN01106754 A CN 01106754A CN 1371682 A CN1371682 A CN 1371682A
- Authority
- CN
- China
- Prior art keywords
- parts
- zinc undecylenate
- ointment
- methylamino
- beriberi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010047601 Vitamin B1 deficiency Diseases 0.000 title claims abstract description 18
- 208000002894 beriberi Diseases 0.000 title claims abstract description 18
- 229940118257 zinc undecylenate Drugs 0.000 title claims description 14
- 239000002674 ointment Substances 0.000 title claims description 13
- -1 Compound zinc undecylenate Chemical class 0.000 title claims description 7
- 239000003814 drug Substances 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims abstract description 3
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical class OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 14
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims description 12
- 229960002703 undecylenic acid Drugs 0.000 claims description 12
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 11
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 11
- 244000125380 Terminalia tomentosa Species 0.000 claims description 11
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 11
- 125000004494 ethyl ester group Chemical group 0.000 claims description 11
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 11
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 239000003961 penetration enhancing agent Substances 0.000 claims description 7
- GAAKLDANOSASAM-UHFFFAOYSA-N undec-10-enoic acid;zinc Chemical compound [Zn].OC(=O)CCCCCCCCC=C GAAKLDANOSASAM-UHFFFAOYSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical class OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 abstract description 4
- 206010048768 Dermatosis Diseases 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 239000005995 Aluminium silicate Substances 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 abstract 1
- 229910000323 aluminium silicate Inorganic materials 0.000 abstract 1
- 235000012211 aluminium silicate Nutrition 0.000 abstract 1
- ZWZFHYVGXDEGGN-UHFFFAOYSA-N ethyl 2-(dimethylamino)dodecanoate Chemical compound CCCCCCCCCCC(N(C)C)C(=O)OCC ZWZFHYVGXDEGGN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 11
- 150000003751 zinc Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 229960003639 laurocapram Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000629 anti-dermatophyte Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000223 dermal penetration Toxicity 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GRKXKNLRBZVLSN-UHFFFAOYSA-N methylamino acetate Chemical compound CNOC(C)=O GRKXKNLRBZVLSN-UHFFFAOYSA-N 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The medicine preparation for curing beriberi dermatosis of formed from undercylenic acid and its zine salt, ethyl dimethylaminolaurate, magnesium aluminium silicate and polyethylene glycol 400. It is a medicine preparation for resisting mycotin infection.
Description
Content of the present invention belongs to the preparing technical field of heavy chemicals, relates to a kind of pharmaceutical preparation that can be used for treating the dermopathic anti-fungal infection of beriberi class.
Traditional route of administration that is used for the treatment of dermatosis class antifungal drug is that medicine is applied directly to the patient affected part, make medicine by dermal osmosis in human body linked groups, to realize the purpose of treatment disease.In recent years, along with medical domain understanding in depth to skin texture, function and metabolic Biochemical processes, people find gradually and recognize, because human body skin and mucosal tissue have powerful barrier action, the effect of traditional transdermal penetration administering mode is very limited, medicine is difficult to infiltrate into region of interest, reaches activity, thereby has greatly influenced clinical efficacy.The various medicines that are used for the treatment of anti-dermatophytes infection such as beriberi, tinea cruris, tinea corporis that can see on the market at present can not infiltrate skin owing to its antibiotic composition, can't kill the skin corium fungal infection, all existing defectives such as the length course of treatment, weak curative effect, disease relapse rate height in varying degrees, and some are used for the treatment of the footwear, shoe pad, socks of beriberi and bathe product such as foot Chinese medicine preparation even be that cost is pursued clinical cure rate to cause the necrosis of disease sites epidermis.The pathology general knowledge of dermatological is told us, cure the high common skin diseases of this class relapse rate of beriberi, key factor is to make antibacterials can see through mucocutaneous barrier, kill the fungal infection of skin corium, its a kind of mode preferably is by means of skin penetration enhancer medicine fully to be penetrated in the linked groups by skin.But present skin penetration enhancer in usefulness known in this field, as dimethyl sulfoxide (Dimethyl Sulfoxide, DMSO), laurocapram (Laurocapram, Azone) etc., the actual clinical effect is all not ideal enough, they make the permeability changes of epithelial cell membrane by softening skin keratoprotein and the proteic mode of solidified structure, in the hope of strengthening the osmosis of medicine, skin, mucosal tissue are had stimulation and destruction inevitably, thereby also reduced the safety and the effectiveness of its use.
The objective of the invention is to overcome the aforementioned existing in prior technology weak point in this area, the compound zinc undecylenate ointment for treating beriberi that a kind of side of system science is provided and has good skin-penetrating therapeutic effect and security performance.
The preparation scheme of pharmaceutical preparation of the present invention is that the designer develops acquisition on the modern pharmacology experiment basis and according to clinical practice for many years, it is a basic recipe with undecylenic acid and the zinc salt thereof that beriberi class dermatosis is had fabulous curative effect, make skin penetration enhancer---two methylamino Laurel ethyl ester (Dodecyl (N with a kind of by long chain alkanol and aminoacid combination, N-dimethylamino) acetate) be auxiliary formula, with Magnesiumaluminumsilicate (SM gel) is thickening and stabilizing agent, with PEG400 (PEG400) is solvent, after science processing, formed and be exclusively used in the dermopathic transdermal administration ointment formulation of treatment beriberi class, because the effect of two methylamino Laurel ethyl esters in the said preparation, strengthen the dermal osmosis effect of undecylenic acid and zinc salt pharmaceutical compositions thereof greatly, thereby reached the dermopathic purpose of effective treatment beriberi class.
The material compositing formula of compound zinc undecylenate ointment for treating beriberi of the present invention is such: contain 5～10 parts of undecylenic acids, 18～22 parts of Zinc Undecylenate, 5～10 parts of two methylamino Laurel ethyl esters, 3～5 parts of Magnesiumaluminumsilicates (SM gel) in the finished product unguentum of formed per 100 parts of unit of weights, all the other are PEG400 (PEG400) solvent.
The actual product of this compound zinc undecylenate ointment for treating beriberi obtains according to following preparation process: (1), taking polyethylene glycol 400 solvents, heating in water bath to 100 ℃, under stirring, add undecylenic acid and Zinc Undecylenate successively, powerful at a high speed the stirring 20～45 minutes fully dissolved medicine; (2), will be cooled to 20～30 ℃ through the solution that obtains behind the said process, add Magnesiumaluminumsilicate and two methylamino Laurel ethyl esters, powerful at a high speed the stirring after 1 hour promptly obtains product.
In material formula of the present invention, be that a kind of molecular structural formula by long chain alkanol and aminoacid be combined into is CH as two methylamino Laurel ethyl esters of skin penetration enhancer
3(CH
2)
nCR
3R
4OCOCHRNR
1R
2The two methylamino acetate preparations of long chain alkanol, n represents one from 4 to 18 integer in the formula, R is hydrogen, C
1To C
7Alkyl, benzyl or 4-hydroxy benzenes, R
1And R
2Be one group of material, comprise hydrogen or C
1To C
7Alkyl, or R
1And R
2The various heterocyclic compounds that the nitrogen-atoms that is connected with them forms, R
3And R
4For another group material, comprise hydrogen, methyl or ethyl.
Two methylamino Laurel ethyl esters can dissolve the lipomicron in skin and mucosal tissue epithelial cell gap under 0.5%～40% concentration, make medicine pass through the iuntercellular effusion to linked groups, because it is not to keratodermatitis and epithelial cell generation effect, therefore can injured skin and mucous epithelium.Long chain alkanol and aminoacid are decomposed in reinforcing agent can be organized emiocytosis immediately after entering tissue esterase (esterases) cutting, absorb thereby further be organized institute's metabolism.After removing this acting factor of dermal penetration enhancer, the lipomicron in epithelial cell gap can solidify again automatically, thereby can not produce stimulation and harm to skin and mucosal tissue, and after using, the patient allergic phenomena can not take place yet, have no side effect and untoward reaction.This dermal penetration enhancer is compared with the like product laurocapram, and the speed that bioactive substance can be higher than 5～6 times of laurocaprams arrives site of action by epithelium and mucosal barrier, thereby has greatly strengthened the curative effect of medicine.
The active ingredient of compound recipe zinc undecylenate ointment is undecylenic acid and zinc salt (Zinc Undecylenate) thereof, its raw material is cheap, system side is simple, curative effect is determined, it is traditional anti-dermatophyte pharmaceutical formulation cited in the state-promulgated pharmacopoeia, the present invention can make undecylenic acid and zinc salt and two methylamino Laurel ethyl ester generation chemical bond reaction by the technology of preparing of special use, after tested, the speed that medicine can be higher than 480 times of no transdermal agent groups in the unit interval penetrates subcutaneous, and infiltration capacity is 5～6 times of known similar transdermal agent laurocapram at present.
Another key content of the present invention is the compatibility technology of undecylenic acid and zinc salt and other composition.The oil-based solvent that undecylenic acid and zinc salt thereof are water insoluble and general, conventional formulation is to add a large amount of dispersion and stabilizing agent in the aqueous solution of undecylenic acid and zinc salt thereof, this method is dry easily, be unfavorable for prolonging the shelf life of medicine and intensive abnormal flavour is arranged, because medicine is not with solution mode compatibility, be unfavorable for that percutaneous absorbs, and can only act on skin surface.The present invention fills a prescription and adopts PEG400 is solvent, makes thickening and stabilizing agent with Magnesiumaluminumsilicate.Polyethylene Glycol is by oxirane and water or ethylene glycol progressively addition and a kind of water solublity straight chain polymer of making, and according to varying in size of relative molecular mass, its physical aspect can be from the mucus of white until hard waxy solid.The molecular weight of PEG400 is 380～420, is colourless heavy-gravity liquid at normal temperatures, can dissolve undecylenic acid and zinc salt thereof fully under 100 ℃ high temperature, and keeps stable at normal temperatures; Therefore in addition, PEG400 is the nonionic atent solvent, and is under general condition highly stable, can not react with transdermal agent isoreactivity material and has influence on clinical effectiveness.The U.S., Japan and the European Community are listed Polyethylene Glycol in the food additive in, and its prescription has mildness, use back skin wet, softness, the joyful aftersensation of using is arranged.The SM gel is by the refining natural inorganic stick that forms of the Ore that contains Magnesiumaluminumsilicate, be odorless, slightly astringent taste, do not fire, the white powder of the soft cunning of quality, its safety non-toxic, the solution dispersion does not have sticking tower and greasy feeling, in PEG400 after long-time high-speed stirred high degree of dispersion, be overlapped to form network structure, make multiple free solution system change constraint solution in the network structure into, form the thixotropy gel of non-newtonian fluid type, have suspension and the unlimited reversible thixotropy of gel under external force; The chemical stability of this gelatinous mass is good, compatibility is good, and not oxidation, azymic have thickening property, diffusibility, suspension and water holding performance of keeping humidity preferably, and have certain heat resistance and heat stability.Experiment confirm, PEG400 and a small amount of SM gel compatibility neither can influence the osmotic effect of transdermal agent, and help giving full play to the curative effect of medicine.
Compared with prior art, novelty of the present invention is to cooperate with undecylenic acid and zinc salt thereof with skin penetration enhancer, formed novel anti-dermatophyte medicine, the speed that it can be higher than 5～6 times of traditional remedies medications arrives site of action by the epithelium barrier, its pharmaceutical formulation is safe and convenient to use, have no side effect, do not have skin irritation and allergic phenomena takes place, and eliminated the intensive abnormal smells from the patient of traditional beriberi paste class medicine, be easy to be accepted, thereby its product has boundless market prospect by the patient.
Application Example
1, preparation technology: get mass fraction and be 69% PEG400 solvent, heating in water bath to 100 ℃, add mass fraction successively and be 5% undecylenic acid and mass fraction under stirring and be 18% Zinc Undecylenate, powerful at a high speed the stirring 0.5 hour fully dissolved medicine; Solution is cooled to 25 ℃, adds mass fraction and be 3% SM gel and mass fraction and be two methylamino Laurel ethyl esters of 5%, powerful at a high speed the stirring after 1 hour, formation product.
2, using method: clean the affected part, evenly smear ointment, fully rub.Medication for the first time is after 7 days, and medication once gets final product again.This product is a medicine for external use, forbids to enter the mouth.
3, observation of curative effect: the pilot scale stage is accepted 37 vitamin B1 deficiency patients of this medicine ointment treatment except that 1 example is invalid, and all the other 36 patients all once cure, and cure rate is 97.3%, and no case was recurrence to follow up a case by regular visits to 45 days.
Claims (2)
1, a kind of dermopathic compound zinc undecylenate ointment for treating beriberi of beriberi class that is used for the treatment of, it is characterized in that in the finished product unguentum of per 100 parts of unit of weights, containing 5～10 parts of undecylenic acids, 18～22 parts of Zinc Undecylenate, 5～10 parts of two methylamino Laurel ethyl esters, 3～5 parts of Magnesiumaluminumsilicates, all the other are the PEG400 solvent, wherein used two methylamino Laurel ethyl esters are that a kind of molecular structural formula is CH
3(CH
2)
nCR
3R
4OCOCHRNR
1R
2Skin penetration enhancer, n represents one from 4 to 18 integer in the formula, R is hydrogen, C
1To C
7Alkyl, benzyl or 4-hydroxy benzenes, R
1And R
2Be one group of material, comprise hydrogen or C
1To C
7Alkyl, R
3And R
4For another group material, comprise hydrogen, methyl or ethyl.
2, be exclusively used in the method for preparing the described compound zinc undecylenate ointment for treating beriberi of claim 1, it is characterized in that comprising following preparation process:
2.1 taking polyethylene glycol 400 solvents, heating in water bath to 100 ℃ adds undecylenic acid and Zinc Undecylenate successively under stirring, and powerful at a high speed the stirring 20～45 minutes fully dissolved medicine;
2.2 the solution that will obtain after 2.1 processes is cooled to 20～30 ℃, adds Magnesiumaluminumsilicate and two methylamino Laurel ethyl ester, powerful at a high speed the stirring 1 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011067543A CN1178649C (en) | 2001-02-21 | 2001-02-21 | Compound zinc undecylenate ointment for treating beriberi |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011067543A CN1178649C (en) | 2001-02-21 | 2001-02-21 | Compound zinc undecylenate ointment for treating beriberi |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1371682A true CN1371682A (en) | 2002-10-02 |
| CN1178649C CN1178649C (en) | 2004-12-08 |
Family
ID=4655728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011067543A Expired - Fee Related CN1178649C (en) | 2001-02-21 | 2001-02-21 | Compound zinc undecylenate ointment for treating beriberi |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1178649C (en) |
-
2001
- 2001-02-21 CN CNB011067543A patent/CN1178649C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1178649C (en) | 2004-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS63500171A (en) | Pharmaceutical vehicles for reducing transdermal flow | |
| KR20190037229A (en) | A synergistic antifungal composition and method thereof | |
| CN100420439C (en) | Use of biguanide derivatives for the preparation of a medicinal product with cicatrizing effect | |
| CN102949709A (en) | External gel used for treating diabetic foot, and preparation method and application thereof | |
| CN101972225A (en) | Pirfenidone-contained gel composition | |
| EP3842030A2 (en) | Semi-solid, oil-based pharmaceutical compositions containing pirfenidone for application in tissue repair | |
| WO2004067012A1 (en) | Limposomes containing asiaticoside and the uses thereof | |
| CN101559077A (en) | Gargle for relieving pain for oral inflammation disease | |
| CN104666496A (en) | Menthol ointment and preparation process thereof | |
| CN106389139A (en) | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| RU2450816C2 (en) | Compositions of hyaluronic acid salt for epithelial damages | |
| CN105267866A (en) | Emulsion for treating onychomycosis and preparation method of emulsion for treating onychomycosis | |
| JP2000297044A (en) | Transdermal patch for external use for skin | |
| CN1178649C (en) | Compound zinc undecylenate ointment for treating beriberi | |
| CN104840404B (en) | A kind of cosmetics with deodorization functions and preparation method thereof | |
| JPH10175859A (en) | External preparation for skin for improving water (of chinese medicine idea) | |
| RU2074710C1 (en) | Agent for treatment of suppurative-inflammatory skin processes and mucosa of different etiology | |
| ES2231007B2 (en) | CREAM FOR THE TREATMENT OF PSORIASIS. | |
| CN1371675A (en) | Skin protection spot-removing cream and preparation method thereof | |
| US12303528B2 (en) | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | |
| JPH044300B2 (en) | ||
| ES2958970T3 (en) | Compositions for nails with antifungal properties | |
| JPH0159243B2 (en) | ||
| JP4717970B2 (en) | Antiplasmin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |